Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Harmony Biosciences announced a planned CEO succession: COO and former board member Peter Anastasiou becomes President, CEO and director effective January 1, 2027. Jeffrey M. Dayno retires December 31, 2026 after nine years with the company and will serve as a non-executive advisor throughout 2027. The company reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and confirmed BP-205 multiple ascending dose study data remain on track for Q4 2026.
Key figures
- Guidance
- Full-year 2026 WAKIX net revenue guidance reiterated at $1.0 billion to $1.04 billion
- Transition effective
- January 1, 2027
- Bp205 mad data timing
- Q4 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.